- Home
- HYB vs SKYE Comparison
HYB vs SKYE Comparison
Compare HYB & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYB
- SKYE
- Stock Information
- Founded
- HYB 1987
- SKYE 2012
- Country
- HYB United States
- SKYE United States
- Employees
- HYB N/A
- SKYE N/A
- Industry
- HYB Investment Managers
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- HYB Finance
- SKYE Health Care
- Exchange
- HYB Nasdaq
- SKYE Nasdaq
- Market Cap
- HYB 194.0M
- SKYE 172.9M
- IPO Year
- HYB 1999
- SKYE N/A
- Fundamental
- Price
- HYB $8.28
- SKYE $6.35
- Analyst Decision
- HYB
- SKYE Strong Buy
- Analyst Count
- HYB 0
- SKYE 5
- Target Price
- HYB N/A
- SKYE $18.40
- AVG Volume (30 Days)
- HYB 39.6K
- SKYE 142.7K
- Earning Date
- HYB 01-01-0001
- SKYE 08-09-2024
- Dividend Yield
- HYB 6.67%
- SKYE N/A
- EPS Growth
- HYB N/A
- SKYE N/A
- EPS
- HYB N/A
- SKYE N/A
- Revenue
- HYB N/A
- SKYE N/A
- Revenue This Year
- HYB N/A
- SKYE N/A
- Revenue Next Year
- HYB N/A
- SKYE N/A
- P/E Ratio
- HYB N/A
- SKYE N/A
- Revenue Growth
- HYB N/A
- SKYE N/A
- 52 Week Low
- HYB $6.23
- SKYE $1.44
- 52 Week High
- HYB $7.41
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- HYB 70.40
- SKYE 53.72
- Support Level
- HYB $8.25
- SKYE $5.71
- Resistance Level
- HYB $8.41
- SKYE $6.69
- Average True Range (ATR)
- HYB 0.08
- SKYE 0.73
- MACD
- HYB -0.02
- SKYE 0.12
- Stochastic Oscillator
- HYB 61.43
- SKYE 57.33
About HYB New America High Income Fund Inc. (The)
New America High Income Fund Inc is a diversified, closed‐end management investment company. Its investment objective is to provide high current income while seeking to preserve stockholder capital by investing in a diversified portfolio of high-yield fixed-income securities. The Fund has a leveraged capital structure. The fund invests in fixed-maturity corporate debt securities that are rated less than the investment grade. Its portfolio of investment consists of investments in different sectors such as energy, financial, cable operators, healthcare, and others.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.